The societal impact of early intensified treatment in patients with type 2 diabetes mellitus

被引:7
作者
Tsotra, Foteini [1 ]
Kappel, Mathias [2 ]
Peristeris, Platon [1 ]
Bader, Giovanni [3 ]
Levi, Eva [1 ]
Lister, Nicola [4 ]
Malhotra, Ankur [5 ]
Ostwald, Dennis A. [2 ,6 ]
机构
[1] WifOR Inst, Athens, Greece
[2] WifOR Inst, Darmstadt, Germany
[3] Novartis Pharma AG, Basel, Switzerland
[4] Novartis Global Hlth & Sustainabil, Johannesburg, South Africa
[5] Novartis India Ltd, Mumbai, Maharashtra, India
[6] Steinbeis Univ, Grad Sch, SIBE, Fac Leadership & Management, Berlin, Germany
关键词
antidiabetes treatment; diabetes complications; early intensified treatment; metformin monotherapy; productivity costs; societal impact; type 2 diabetes mellitus; CARDIOVASCULAR OUTCOMES; GLUCOSE CONTROL; WORK; RETURN; PREVALENCE; INSULIN; RISK;
D O I
10.2217/cer-2022-0110
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Aim: The current study estimates the societal impact of early intensified treatment compared with initial monotherapy with subsequent treatment intensification in newly diagnosed adults with type 2 diabetes mellitus in Mexico. Methods: An individual patient-level simulation and a static cohort model were employed to simulate the treatment pathway and the probability of experiencing complications of diabetes. The avoided number of events was translated into avoided productivity losses, which were monetized using wages. Results: Patients on early intensified treatment experienced approximately 13,000 fewer complication events over 10 years. This was translated into a societal impact of $54 million (USD). Conclusion: Early treatment intensification is likely to be of particular benefit to health outcomes and productivity losses.
引用
收藏
页码:1185 / 1199
页数:15
相关论文
共 63 条
  • [1] First-line Treatment with Empagliflozin and Metformin Combination Versus Standard Care for Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease in Qatar. A Cost-Effectiveness Analysis
    Abushanab, Dina
    Al-Badriyeh, Daoud
    Liew, Danny
    Ademi, Zanfina
    [J]. CURRENT PROBLEMS IN CARDIOLOGY, 2022, 47 (06)
  • [2] Barriers for conducting clinical trials in developing countries- a systematic review
    Alemayehu, Chalachew
    Mitchell, Geoffrey
    Nikles, Jane
    [J]. INTERNATIONAL JOURNAL FOR EQUITY IN HEALTH, 2018, 17
  • [3] 6. Glycemic Targets: Standards of Medical Care in Diabetes-2021
    不详
    [J]. DIABETES CARE, 2021, 44 : S73 - S84
  • [5] [Anonymous], Global report on diabetes
  • [6] [Anonymous], Life tables
  • [7] [Anonymous], 2021, OECD Stat
  • [8] Attarchi M, 2012, INT J COLLAB RES INT, V4, P1305
  • [9] Diabetes in Mexico: cost and management of diabetes and its complications and challenges for health policy
    Barquera, Simon
    Campos-Nonato, Ismael
    Aguilar-Salinas, Carlos
    Lopez-Ridaura, Ruy
    Arredondo, Armando
    Rivera-Dommarco, Juan
    [J]. GLOBALIZATION AND HEALTH, 2013, 9
  • [10] Alternative valuations of work loss and productivity
    Berger, ML
    Murray, JF
    Xu, J
    Pauly, M
    [J]. JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 2001, 43 (01) : 18 - 24